Table 4.

Use of Palivizumab in preterm infants and adjusted odds ratios (AOR) by several characteristics; Rome, Italy 2000-2006

		Yes		p value	AOR	(95%CI)	p value
		N	%
Age of the mother (years)	≤ 32 (REF)	118	10.5	<0.01	1.00		<0.01
	>32	206	16.0		1.67	(1.22 -2.30)
Parity	0 (REF)	221	15.2	<0.01		-
	1	72	10.6		0.83	(0.58 -1.18)	0.30
	>1	31	11.4		0.92	(0.55 -1.54)	0.74
Years of education of the mother	≤ 8 years (REF)	137	12.6	0.20	1.00	-
	>8 years	186	14.1		1.14	(0.84 -1.54)	0.42
	Not known	1	25.0		NE	-
Country of birth of the mother	Italy (REF)	283	13.8	0.23	1.00	-	<0.01
	Other	41	11.4		0.47	(0.30 0.73)
Gender	Male (REF)	160	12.5	0.13	1.00	-
	Female	164	14.6		1.34	(1.00 1.80)	0.05
Year of birth	2000 (REF)	9	2.8	<0.01	1.00	-
	2001	22	7.0		2.48	(1.02 -6.00)	0.04
	2002	41	13.0		7.00	(3.05 -16.02)	<0.01
	2003	47	13.0		9.37	(4.13 -21.28)	<0.01
	2004	73	18.4		13.88	(6.23 -30.93)	<0.01
	2005	61	18.3		17.90	(7.87 -40.67)	<0.01
	2006	71	19.1		18.43	(8.19 -41.46)	<0.01
Birth weight (grams)	<1000 (REF)	76	50.0	<0.01	1.00	-
	1000-2000	209	26.6		1.22	(0.75 -1.99)	0.42
	>2000	39	2.6		0.18	(0.10 -0.34	<0.01
Gestational age (weeks)	<32 (REF)	221	42.8	<0.01	1.00	-
	32-35	103	5.4		0.19	(0.13 -0.27)	<0.01
Bronchodysplasia	Yes (REF)	41	67.2	<0.01	5.96	(2.90 -12.26)	<0.01
	No	283	12.1			-
Apgar score	≤ 7	128	32.4	<0.01	1.55	(1.10 -2.19)	0.01
	>7 (REF)	196	9.7			-
Month of birth	Jan-Mar	71	12.6	<0.01	1.57	(1.00 -2.45)	0.05
	Apr-Jun (REF)	68	11.4		1.00	-
	Jul-Sep	99	15.3		2.00	(1.32 -3.03)	<0.01
	Oct-Dec	86	14.4		2.12	(1.38 -3.26)	<0.01
Congenital heart disease (CHD)	Yes (REF)	0	0.0	0.02	1.00	-
	No	324	13.6		NE	-
Total		324	13.5

AOR: Adjusted odds ratio of administration of Palivizumab; REF: reference group; NE: not estimable